Biocon targets top global insulin supplier in 5 years

Why Biocon is sharpening its insulin ambition

Biocon Ltd. says it wants to become the world’s top supplier of insulin in the coming years, banking on rising demand for the therapy as larger pharmaceutical companies shift resources toward newer diabetes and obesity drugs. Kiran Mazumdar-Shaw, co-founder and Executive Chairperson of Biocon, said the company believes scale and manufacturing capability can help it capture the opportunity. Speaking in an interview with Bloomberg Television’s Latitude with Haslinda Amin, she said Biocon could become the number one insulin company globally in five years. The company is currently the third-largest insulin supplier by volume worldwide, according to her comments.

The push comes as the global insulin market, estimated at about $10 billion, faces changing competitive dynamics. Mazumdar-Shaw pointed to Big Pharma’s increasing focus on next-generation metabolic therapies such as glucagon-like peptides (GLP-1s). That shift, she suggested, is creating room for manufacturers willing to invest in insulin capacity and delivery formats.

What Mazumdar-Shaw said about the five-year target

Mazumdar-Shaw said, “In five years, we could be the number one insulin company in the world,” adding that Biocon is among a small group of companies globally with the scale needed to pursue that target. In separate remarks reported alongside the same theme, she also described a market context where “big companies want to exit the insulin business” and focus on GLP-1 drugs.

She highlighted product-format choices as a differentiator, saying larger companies want to make insulin only in vials, while “nobody wants to make insulin in pens and cartridges.” She added that Biocon makes insulin in pens and cartridges, positioning it to serve segments where device-based delivery is important.

Where Biocon stands in insulin today

Biocon manufactures generic drugs and biosimilars, which are highly similar versions of branded biological medicines and typically sold at lower prices. In insulin, Mazumdar-Shaw said Biocon is already the third-largest supplier by volume globally. She also said the company has invested “big time” to ramp up production capacity, signalling an intent to compete on both volume and reliability of supply.

Alongside Mazumdar-Shaw’s target, Biocon’s leadership has also discussed market-share aspirations. Shreehas Tambe, the company’s managing director and CEO, said Biocon aims to capture 20 percent of the global insulin market in five years. Mazumdar-Shaw added that Biocon has identified 20 emerging markets as growth markets and wants to reach “one in five insulin-dependent patients” over the same period.

Capacity plans and Malaysia expansion milestones

A February 2026 update from Axis Securities said Biocon’s “steady” insulin business is expected to double drug product capacity at its Malaysia facility by FY27. The same note said drug substance expansion would follow in FY28-29. These timelines matter because insulin leadership is largely a scale and execution game, with manufacturing reliability, device formats, and regulatory compliance determining how quickly companies can expand across markets.

Biocon’s stated intent to invest into capacity aligns with its broader thesis that incumbents are reallocating attention to GLP-1s. If that trend holds, the availability of large, quality-assured insulin capacity could become a more visible competitive edge for suppliers serving health systems focused on affordability.

GLP-1 strategy: selective markets, cautious pricing

Biocon is also preparing to enter the market for GLP-1 receptor agonists, the class that includes widely known brands such as Ozempic and Mounjaro. But Mazumdar-Shaw described generic GLP-1s as crowded, saying Biocon is realistic about the extent of global competition. She also said prices for these drugs are hitting “rock bottom” in India.

In that context, she said Biocon does not plan to sell its generic versions of semaglutide in India. Instead, she described a measured approach focused on select markets, with Biocon seeing some opportunity for GLP-1s in Canada and also targeting Latin America (including Brazil), the Middle East, and Southeast Asia.

The company’s “value maximisation” lens for insulin vs GLP-1

Mazumdar-Shaw said Biocon follows a “value maximisation” approach, where capital allocation is guided by relative margins between insulin and GLP-1 therapies. She said the company would look at pricing and assess whether insulin offers better margins than GLP-1s, and then tilt manufacturing focus accordingly.

This framing links Biocon’s insulin ambition to discipline on returns rather than only volume growth. It also reflects the reality that off-patent GLP-1 drugs can be competitively priced in emerging markets, limiting profitability even when demand is strong.

Pipeline progress: liraglutide and semaglutide filings

On GLP-1s, Biocon is building a pipeline alongside its insulin franchise. The Axis Securities update said liraglutide launches in Europe have supported generics growth, with further expansion planned in the US and Latin America. It also said semaglutide filings are underway in multiple international markets.

Separately, the broader competitive landscape in India has seen pricing moves, including references to Novo Nordisk cutting prices on weight-loss and diabetes medications in the country. These changes add to the pricing sensitivity that Mazumdar-Shaw highlighted when discussing why Biocon is not planning an India launch for generic semaglutide.

What this could mean for patients and payers

Biocon’s focus on insulin and biosimilars is closely tied to affordability, as biosimilars and generics are typically priced lower than originator products. If Biocon expands supply meaningfully, it could support procurement for health systems that face growing diabetes prevalence and cost pressure.

At the same time, the company’s cautious stance on India semaglutide underscores how pricing dynamics can influence access strategies. When prices fall quickly in highly competitive markets, companies may prioritise regions where reimbursement, pricing frameworks, and regulatory pathways support sustainable supply.

Key facts at a glance

What to watch next

The next concrete markers will be execution against the Malaysia capacity timeline through FY27 and the subsequent drug substance expansion plan in FY28-29. On the GLP-1 side, progress is likely to be tracked through additional liraglutide expansion in the US and Latin America and updates on semaglutide filings in international markets.

For investors and industry observers, the story will hinge on how successfully Biocon balances scale-driven insulin growth with selective participation in GLP-1s, using its stated margin-led “value maximisation” approach. The company’s five-year goal sets a clear benchmark, while the capacity milestones provide a near-term map for measuring delivery.